PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608833
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1608833
The percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market is estimated to be valued at USD 2.59 Bn in 2024 and is expected to reach USD 4.93 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 2.59 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 9.60% | 2031 Value Projection: | 4.93 Bn |
Percutaneous transluminal coronary angioplasty (PTCA) balloon catheter aims to widen clogged or narrowed coronary arteries to restore proper blood flow to the heart. PTCA is a non-surgical procedure that involves inserting a slender tube called a catheter into an artery, usually in the groin area, and guided it into the coronary arteries using X-ray images to find the clog or narrowing. Once located, a small deflated balloon at the tip of the catheter is inflated, compressing and flattening the plaque to widen the artery. After deflation and removal of the catheter, an empty metal mesh tube called a stent may be placed to keep the artery open. PTCA is considered revolutionary technique that revolutionized treatment of coronary artery disease.
Global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market is expected to witness high growth due to the rising prevalence of cardiovascular diseases and the increasing preference for PTCA balloon catheters over open-heart surgeries. Additionally, growing geriatric population, which is more prone to cardiovascular diseases, along with technological advancements in PTCA balloon catheters, further contributes to this market expansion. However, stringent regulatory approval process for new product launches and availability of alternative treatment modality like drug-eluting stents are restraining the market growth. Development of affordable and innovative bioabsorbable stents and advent of new generation drug coated balloons present high growth opportunities for market players.
This report provides in-depth analysis of the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Boston Scientific Corporation, Cardinal Health, BD, Medtronic, Terumo Medical Corporation, Cook Medical, Biotronik, AndraTec, Natec Medical, Shockwave Medical Inc, Nipro Group Companies, Teleflex Incorporated, and MicroPort Scientific Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market